福斯瑞匹坦三联预防 vs 双联疗法用于高风险妇科手术后恶心呕吐:一项单中心RCT
Triple prophylaxis with fosaprepitant versus dual therapy for postoperative nausea and vomiting in high-risk gynecologic surgery
韩国三星医疗中心一项单中心、双盲、随机对照试验比较地塞米松+帕洛诺司琼+福斯瑞匹坦三联预防与地塞米松+帕洛诺司琼双联预防在下颌静脉全麻(TIVA)高风险腹腔镜妇科手术患者中的效果。
三星医疗中心单中心RCT给出高风险妇科手术患者三药预防PONV较双药更有效的具体数据,可直接参考用药方案。
- Article
- Open access
- Published: 15 October 2026
- Yeon Ji Noh1 na1,
- Yu Jeong Bang1 na1,
- Yoo-Young Lee2,
- Joonsuk Bom1,
- Kwang Hyun Lee1 &
- …
- Heejoon Jeong1
Scientific Reports (2026) Cite this article
We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.
Abstract
Although current guidelines for postoperative nausea and vomiting (PONV) recommend multimodal prophylaxis for patients with multiple risk factors, evidence regarding the optimal triple-agent regimen for high-risk patients undergoing laparoscopic gynecologic surgery under total intravenous anesthesia (TIVA) remains limited. This single-center, double-blind, randomized controlled trial investigated the efficacy of triple prophylaxis with dexamethasone, palonosetron, and fosaprepitant compared to common dual prophylaxis with dexamethasone and palonosetron. Female patients aged 19–50 years, classified as American Society of Anesthesiologists physical status I or II, and scheduled for elective laparoscopic gynecologic surgery under TIVA between August 2023 and July 2025 were randomized to receive either dual or triple therapy. The primary outcome was the incidence of PONV within 24 h postoperatively. A total of 140 patients were analyzed. The results demonstrated that triple prophylaxis significantly reduced the incidence of PONV during the first 24 h postoperatively compared with dual therapy (27.1% vs. 47.9%; odds ratio: 0.38; 95% confidence interval: 0.19 to 0.78; p = 0.008). In conclusion, triple prophylaxis incorporating intravenous dexamethasone, palonosetron, and fosaprepitant is more effective than dual therapy for preventing PONV in high-risk patients undergoing laparoscopic gynecologic surgery under TIVA.
Acknowledgements
Not applicable.
Funding
Support was provided solely by institutional sources.
Author information
Author notes
Yeon Ji Noh and Yu Jeong Bang have contributed equally to this work.
Authors and Affiliations
Department of Anesthesiology and Pain Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, South Korea
Yeon Ji Noh, Yu Jeong Bang, Joonsuk Bom, Kwang Hyun Lee & Heejoon Jeong
Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Yoo-Young Lee
Authors
- Yeon Ji Noh
- Yu Jeong Bang
- Yoo-Young Lee
- Joonsuk Bom
- Kwang Hyun Lee
- Heejoon Jeong
Corresponding author
Correspondence to Heejoon Jeong.
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Noh, Y.J., Bang, Y.J., Lee, YY. et al. Triple prophylaxis with fosaprepitant versus dual therapy for postoperative nausea and vomiting in high-risk gynecologic surgery. Sci Rep (2026). https://doi.org/10.1038/s41598-026-76554-1
Received: 01 June 2026
Accepted: 14 October 2026
Published: 15 October 2026
DOI: https://doi.org/10.1038/s41598-026-76554-1
Keywords
来源:Nature 健康护理主题 · nature.com